Valence8 US’s Apogee Therapeutics APGE Stock Holding History

Valence8 US’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,240	Closed	-$308K	–	16
2024 Q3	$308K	Buy	+5,240	New	+$251K	0.13%	34

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Valence8 US's APGE Position: Q4 2024 in Review

Valence8 US sold out of Apogee Therapeutics (APGE) in Q4 2024, closing a stake of 5,240 shares — an estimated $308K sold.

Valence8 US first reported a position in APGE in Q3 2024 and held it in 1 quarter. The position peaked at $308K in Q3 2024. 157 funds tracked by Wall St. Rank hold APGE as of Q4 2024.

Valence8 US reported no remaining Apogee Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 5,240 Apogee Therapeutics shares in Q4 2024, an estimated $308K.
Valence8 US first reported a position in Apogee Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's Apogee Therapeutics position peaked at $308K in Q3 2024.
157 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.